News & Updates

In lung cancer patients undergoing platinum-based doublet chemotherapy, oral compound probiotic supplements may improve their quality of life (QoL) and relieve gastrointestinal (GI) side effects related to their chemo regimen.

A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.

Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.

Daily supplementation with melatonin, zinc, and multivitamins cuts the duration of COVID-19 or COVID-19-like symptoms, thus supplementing the COVID-19 treatment armamentarium, a study has shown.

Use of anlotinib combined with etoposide and carboplatin (EC; chemotherapy) as first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) yields a significantly improved progression-free survival (PFS) as well as overall survival (OS) benefits when compared with chemotherapy, according to data from the phase III ETER701 trial presented at ELCC 2024.

Patients with familial pulmonary fibrosis (FPF) share an equally aggressive disease progression as those with sporadic idiopathic pulmonary fibrosis (IPF) even though they are younger and less exposed to tobacco, reveals a study.

Post-exposure prophylaxis with the probiotic Lacticaseibacillus rhamnosus GG (LGG) led to prolonged time to COVID-19 infection, reduced incidence of symptoms, and gut microbiome changes, but not overall incidence, a study suggests.